Journal of Medicinal Chemistry
ARTICLE
has potent antitumor effects and augments antibody-mediated cytotoxi-
city via a novel immune mechanism. Cancer Res. 2004, 64, 5471–5480.
(2) Kubota, T.; Flentke, G. R.; Bachovchin, W. W.; Stollar, B. D.
Involvement of dipeptidyl peptidase IV in an in vivo immune response.
Clin. Exp. Immunol. 1992, 89, 192–197.
(3) Kelly, T. A.; Adams, J.; Bachovchin, W. W.; Barton, R. W.;
Campbell, S. J.; Coutts, S. J.; Kennedy, C. A.; Snow, R. J. Immunosup-
pressive boronic acid dipeptides: correlation between conformation and
activity. J. Am. Chem. Soc. 1993, 115, 12637–12638.
(4) Mentlein, R.; Gallwitz, B.; Schmidt, W. E. Dipeptidyl-peptidase
IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-
1(7-36)amide, peptide histidine methionine and is responsible for
their degradation in human serum. Eur. J. Biochem. 1993, 214, 829–835.
(5) Kieffer, T. J.; McIntosh, C. H.; Pederson, R. A. Degradation of
glucose-dependent insulinotropic polypeptide and truncated glucagon-
like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinol-
ogy 1995, 136, 3585–3596.
Ksiazek, J. F.; Bachovchin, W. W. Structure-activity relationships of
boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2
position of Xaa-boroPro dipeptides. J. Med. Chem. 1996, 39, 2087–2094.
(19) Cheng, J. D.; Valianou, M.; Canutescu, A. A.; Jaffe, E. K.; Lee,
H. O.; Wang, H.; Lai, J. H.; Bachovchin, W. W.; Weiner, L. M.
Abrogation of fibroblast activation protein enzymatic activity attenuates
tumor growth. Mol. Cancer Ther. 2005, 4, 351–360.
(20) Santos, A. M.; Jung, J.; Aziz, N.; Kissil, J. L.; Purꢀe, E. Targeting
fibroblast activation protein inhibitor tumor stromagenesis and growth
in mice. J. Clin. Invest 2009, 119, 3613–3625.
(21) Jesson, M. I.; McLean, P. A.; Miller, G. T.; Adams, S.; Aubin, J.;
Jones, B. Immune mechanism of action of talabostat: a dipeptidyl
peptidase targeted antitumor agent. In Proceedings of the 98th Annual
Meeting of the American Association for Cancer Research, 2007,
Abstract 1894.
(22) Burkey, B. F.; Hoffmann, P. K.; Hassiepen, U.; Trappe, J.;
Juedes, M.; Foley, J. E. Adverse effects of dipeptidyl peptidases 8 and 9
inhibition in rodents revisited. Diabetes Obes. Metab. 2008,
10, 1057–1061.
(6) Choy, M.; Lam, S. Sitagliptin: a novel drug for the treatment of
type 2 diabetes. Cardiol. Rev. 2007, 15, 264–271.
(7) Traynor, K. FDA approves saxagliptin for type 2 diabetes. Am. J.
Health Syst. 2009, 66, 1513.
(23) Wu, J.; Tang, H.; Yeh, T.; Chen, C.; Shy, H.; Chu, Y.; Chien, C.;
Tsai, T.; Huang, Y.; Huang, Y.; Huang, C.; Tseng, H.; Jiaang, W.; Chao,
Y.; Chen, X. Biochemistry, pharmacokinetics, and toxicology of a potent
and selective DPP8/9 inhibitor. Biochem. Pharmacol. 2009, 78, 203–210.
(24) Snow, R. J.; Bachovchin, W. W.; Barton, R. W.; Campbell, S. J.;
Coutts, S. J.; Freeman, D. M.; Gutheil, W. G.; Kelly, T. A.; Kennedy,
C. A. Studies on proline boronic acid dipeptide inhibitors of dipeptidyl
peptidase IV: identification of a cyclic species containing a B-N bond
J. Am. Chem. Soc. 1994, 116, 10860–10869.
(25) Bodor, N.; Buchwald, P. Soft drug design: general principles
and recent applications. Med. Res. Rev. 2000, 20, 58–101.
(26) Pao, L.; Hsiong, C.; Hu, O. Y.; Wang, J.; Ho, S. In vitro and
in vivo evaluation of the metabolism and pharmacokinetics of sebacoyl
dinalbuphine. Drug Metab. Dispos. 2005, 33, 395–402.
(27) Kane, R. C.; Farrell, R. T.; Sridhara, R.; Pazdur, R. United States
Food and Drug Administration approval summary: bortezomib for the
treatment of progressive multiple myeloma after one prior therapy. Clin.
Cancer Res. 2006, 12, 2955–2960.
(28) Marguet, D.; Baggio, L.; Kobayashi, T.; Bernard, A.; Pierres, M.;
Nielsen, P. F.; Ribel, U.; Watanabe, T.; Drucker, D. J.; Wagtmann, N.
Enhanced insulin secretion and improved glucose tolerance in mice
lacking CD26. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 6874–6879.
(8) Croxtall, J. D.; Keam, S. J. Vildagliptin: a review of its use in the
management of type 2 diabetes mellitus. Drugs 2008, 68, 2387–2409.
(9) Horie, Y.; Hayashi, N.; Dugi, K.; Takeuchi, M. Design, statistical
analysis and sample size calculation of a phase IIb/III study of linagliptin
versus voglibose and placebo. Trials 2009, 10, 82.
(10) Pratley, R. E. Alogliptin: a new, highly selective dipeptidyl
peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin.
Pharmacother. 2009, 10, 503–512.
(11) Connolly, B. A.; Sanford, D. G.; Chiluwal, A. K; Healey, S. E.;
Peters, D. E.; Dimare, M. T.; Wu, W.; Liu, Y.; Maw, H.; Zhou, Y.; Li, Y.;
Jin, Z.; Sudmeier, J. L.; Lai, J. H.; Bachovchin, W. W. Dipeptide boronic
acid inhibitors of dipeptidyl peptidase IV: determinants of potency and
in vivo efficacy and safety. J. Med. Chem. 2008, 51, 6005–13.
(12) Narra, K.; Mullins, S. R.; Lee, H. O.; Strzemkowski-Brun, B.;
Magalong, K.; Christiansen, V. J.; McKee, P. A.; Egleston, B.; Cohen,
S. J.; Weiner, L. M.; Meropol, N. J.; Cheng, J. D. Phase II trial of single
agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in
patients with metastatic colorectal cancer. Cancer Biol. Ther. 2007,
6, 1691–1699.
(13) Eager, R. M.; Cunningham, C. C.; Senzer, N. N.; Stephenson, J.,
Jr.; Anthony, S. P.; O’Day, S. J.; Frenette, G.; Pavlick, A. C.; Jones, B.;
Uprichard, M.; Nemunaitis, J. Phase II assessment of talabostat and
cisplatin in second-line stage IV melanoma. BMC Cancer 2009, 9, 263.
(14) Eager, R. M.; Cunningham, C. C.; Senzer, N.; Richards, D. A.;
Raju, R. N.; Jones, B.; Uprichard, M.; Nemunaitis, J. Phase II trial of
talabostat and docetaxel in advanced non-small cell lung cancer. Clin.
Oncol. 2009, 21, 464–472.
(15) Walsh, M.; Krauss, A. C.; Davis, J. P.; Kim, S. Y.; Guimond, M.;
Mackall, C. L.; Fry, T. J. Dipeptidyl peptidase inhibition accelerates
dendritic cell cross priming of tumor-reactive T cells resulting in
regression of established tumors. In 50th ASH Annual Meeting and
Exposition, 2008, Abstract 2579.
(16) Lankas, G. R.; Leiting, B.; Roy, R. S.; Eiermann, G. J.; Beconi,
M. G.; Biftu, T.; Chan, C. C.; Edmondson, S.; Feeney, W. P.; He, H.;
Ippolito, D. E.; Kim, D.; Lyons, K. A.; Ok, H. O.; Patel, R. A.; Petrov,
A. N.; Pryor, K. A.; Qian, X.; Reigle, L.; Woods, A.; Wu, J. K.; Zaller, D.;
Zhang, X.; Zhu, L.; Weber, A. E.; Thornberry, N. A. Dipeptidyl peptidase
IV inhibition for the treatment of type 2 diabetes: potential impor-
tance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005,
54, 2988–2994.
(17) Feng, J.; Zhang, Z.; Wallace, M. B.; Stafford, J. A.; Kaldor, S. W.;
Kassel, D. B.; Navre, M.; Shi, L.; Skene, R. J.; Asakawa, T.; Takeuchi, K.;
Xu, R.; Webb, D. R.; Gwaltney, S. L. Discovery of alogliptin: a potent,
selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase
IV. J. Med. Chem. 2007, 50, 2297–2300.
(18) Coutts, S. J.; Kelly, T. A.; Snow, R. J.; Kennedy, C. A.; Barton,
R. W.; Adams, J.; Krolikowski, D. A.; Freeman, D. M.; Campbell, S. J.;
2028
dx.doi.org/10.1021/jm100972f |J. Med. Chem. 2011, 54, 2022–2028